Skip Navigation


Annals of Oncology Advance Access originally published online on September 13, 2006
Annals of Oncology 2006 17(12):1830-1834; doi:10.1093/annonc/mdl305
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/12/1830    most recent
mdl305v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kiewe, P
Right arrow Articles by Nagorsen, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiewe, P
Right arrow Articles by Nagorsen, D
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

melanoma

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma

P Kiewe1, NE Bechrakis2, A Schmittel1, P Ruf3, H Lindhofer4, E Thiel1 and D Nagorsen1,*

1 Department of Hematology, Oncology, and Transfusion Medicine, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
2 Department of Ophthalmology, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
3 TRION Research GmbH, Martinsried, Germany
4 TRION Pharma GmbH, Munich, Germany

* Correspondence to: Dr D. Nagorsen, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, Hindenburgdamm 30, 12200 Berlin, Germany. Tel: +49-30-8445-2337; Fax: +49-30-8445-4468; E-mail: Dirk.Nagorsen{at}charite.de

Background: Metastatic uveal melanoma has a poor prognosis and limited therapeutic options. Proteoglycans are involved in tumor cell invasion and metastatic behavior. The mAbB5 stains a chondroitin sulphate proteoglycan (CSPG) on cutaneous melanoma cells. Here, we compare the B5-staining of CSPG in primaries and metastases of uveal melanoma.

Material and methods: Immunohistopathological staining was performed in 15 cutaneous and 39 uveal melanoma samples. A score for intracellular and surface staining was established. B5 staining was compared in primaries and metastases of uveal melanoma using Student's t-test.

Results: Eight of 11 (73%) uveal melanoma metastases were positive for B5-staining whereas only 5 of 28 (18%) primary uveal melanoma samples were B5-positive (P < 0.001). Nine of 15 cutaneous melanoma samples (60%) were B5-positive without significant difference between primary and metastatic lesions. Surface staining was found both on uveal melanoma metastases and cutaneous melanomas.

Conclusions: CSPG was expressed significantly more often in metastases than in primaries of uveal melanoma. It potentially may be one factor associated with metastatic spread. Further studies are needed to determine its use as prognostic factor. The mAbB5 may also be a promising tool for immunotherapy due to its strong staining of CSPG on the surface of cutaneous and metastatic uveal melanoma cells.

Key words: uveal melanoma, ocular melanoma, chondroitin sulphate proteoglycan, immunotherapy, immunohistochemistry


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.